Document Detail


Association of anemia correction with health related quality of life in patients not on dialysis.
MedLine Citation:
PMID:  17958944     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This was an open-label study to asses the association of changes in hemoglobin with changes in health related quality of life (HRQOL) in patients treated with darbepoetin alfa.
METHODS: Originally, 81 chronic kidney disease (CKD) patients not on dialysis and naïve to erythropoiesis stimulating agents (ESA) were randomly assigned into two open-label groups (3 : 1). As a majority of control group patients opted out of control status, this study reports on the single arm study analysis that was performed on the 48 patients who received the drug through week 16. Sixty-two patients received once-weekly darbepoetin alfa in addition to conservative management for CKD. Instruments that measured general (SF-36, FACTanemia, FACT-fatigue, ADL and IADL) and disease specific (KDQOL) HRQOL domains were administered at baseline and after 8, 16, and 24 weeks.
RESULTS: Compared to baseline values, mean HRQOL subscales were significantly improved in the treatment group at 16 weeks (p < 0.05 for SF-36 physical function; p < 0.001 for SF-36 vitality, FACT anemia and FACT fatigue scales). At week 16, the SF-36 mean increase for 48 treatment patients in the Vitality Subscale Score was 14.9 (SD 3.2) and the mean increase in the KDQOL Burden of Kidney Disease Subscale was 5.5 (SD 3.3). Multivariate regression analysis demonstrated a statistically significant association (p < 0.05) between hemoglobin levels and higher HRQOL scores on several physical function, energy and fatigue scales.
CONCLUSION: Improvements in hemoglobin in CKD patients not on dialysis were associated with statistically significant (p < 0.05), clinically meaningful (> 5 points) HRQOL improvements on scales measuring physical activity, vitality and fatigue. Our study did not show an association between increased hemoglobin levels and other aspects of HRQOL, such as those relating to emotional status, sexual activity or cognition. The interpretation of our results is limited by the lack of a control arm to assess whether conservative therapy for CKD, in the absence of ESA administration, would have a comparable effect on patients' HRQOL scores. Further research needs to examine whether other aspects of HRQOL improve with anemia treatment, in the same way as those aspects of HRQOL more closely related to physical activity and fatigue.
Authors:
Marcus Alexander; Reshma Kewalramani; Irene Agodoa; Denise Globe
Related Documents :
25428634 - Brainstem stroke-related restless legs syndrome: frequency and anatomical considerations.
25237944 - Association of -1382a>g ccl11 gene variant with ischemic stroke, its subtypes and hemor...
660174 - Using neuropsychological and personality tests to assess the likelihood of patient empl...
21288214 - Acceleromyography to assess neuromuscular recovery: is calibration before measurement m...
23233654 - Genome-wide association analysis of anti-tnf drug response in patients with rheumatoid ...
7324874 - Incidence of primary intracranial neoplasms in an isolated population (the faroese) dur...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current medical research and opinion     Volume:  23     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-19     Completed Date:  2008-02-22     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2997-3008     Citation Subset:  IM    
Affiliation:
Harvard University and Beth Israel Deaconess Medical Center, Boston, MA 02138, USA. malexand@fas.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anemia / drug therapy*,  etiology
Erythropoietin / analogs & derivatives*,  therapeutic use
Female
Hematinics / therapeutic use*
Hemoglobins / analysis
Humans
Kidney Failure, Chronic / complications*
Male
Middle Aged
Quality of Life*
Renal Dialysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hematinics; 0/Hemoglobins; 11096-26-7/Erythropoietin; 15UQ94PT4P/darbepoetin alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acting on voices: Omnipotence, sources of threat, and safety-seeking behaviours.
Next Document:  Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line...